The 6 C's of primary sclerosing cholangitis
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many patients with chronic liver disease are at increased risk of developing HCC or cholangiocellular carcinoma.
“Many patients with chronic liver disease are at an increased risk of developing hepatocellular carcinoma (HCC) or cholangiocellular carcinoma.159,160”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [159]
The CHOLANGITIS figure (pp. 1255–1256) says patients with primary sclerosing cholangitis are at increased risk of hepatocellular carcinoma and cholangiocarcinoma. The source concerns this specific chronic liver disease; it does not establish the claim for patients with chronic liver disease more broadly. (LLM, conf=0.86)
Experimental — accuracy not yet measuredHCC is more frequent in patients with zone 3 injury, such as NASH or alcohol-related liver disease, while cholangiocellular carcinoma risk is dramatically increased in patients with persistent periportal injury.
“While HCC is more frequent in patients with zone 3 injury, such as NASH or alcohol-related liver disease,160 cholangiocellular carcinoma risk is dramatically increased in patients with persistent periportal injury, e.g. in those with primary sclerosing cholangitis.159”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [159]
The CHOLANGITIS figure (pp. 1255–1256) identifies cholangiocarcinoma among cancers for which patients with primary sclerosing cholangitis have increased risk, and depicts portal fibrosis. It does not establish that persistent periportal injury generally confers a dramatically increased risk. The HCC comparison is attached to a different citation in the citing sentence. (LLM, conf=0.84)
Experimental — accuracy not yet measuredThe fibrotic wound healing response is tightly linked to zonal injury and changes in hepatocyte identity via reprogramming.
“Likewise, the fibrotic ‘wound healing’ response is tightly linked to zonal injury and changes in hepatocyte identity via reprogramming.155,159,160”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [159]
The Abstract describes fibrosis and bile-duct destruction in primary sclerosing cholangitis, and the CHOLANGITIS passage lists periductal fibrosis. Neither passage addresses a link between a fibrotic wound-healing response, zonal injury, and hepatocyte-identity reprogramming; searches for those terms found no such discussion in our copy. (LLM, conf=0.72)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Trivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.049 · Cited by 183 · see citing works
Self-citationKunzmann, L. K., Schoknecht, T., Poch, T., Henze, L., Stein, S., Kriz, M., Grewe, I., Preti, M., Hartl, J., Pannicke, N., et al. (2020) · Hepatology · doi:10.1002/hep.31140 · Cited by 93 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Rühlemann M, Liwinski T, Heinsen FA, Bang C, Zenouzi R, Kummen M, et al. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther 2019;50(5):580-589.
- Guicciardi ME, Trussoni CE, LaRusso NF, Gores GJ. The spectrum of reactive cholangiocytes in primary sclerosing cholangitis. Hepatology 2020;71(2):741-748.
- Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann MC, Bang C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 2020;69(4):665-672.
- Quraishi MN, Acharjee A, Beggs AD, Horniblow R, Tselepsis C, Gkoutus G, et al. A pilot integrative analysis of colonic gene expression, gut microbiota and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways. J Crohns Colitis 2020;14(7):935-947.
- Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing chol- angitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55(6):588-614.
Cited by
Sorted by citations
Distinct hepatocyte identities in liver homeostasis and regeneration
Chen, F., Schönberger, K., & Tchorz, J. S. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100779 · Cited by 30 · see citing works
- Authors
- Deeb, M., Karlsen, T. H., & Hirschfield, G. M.
- Affiliations
- University Health Network (CA)
- Oslo University Hospital (NO)
- Corresponding author
- Hirschfield, Gideon M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 73
- Issue
- 5
- Pages
- 1255-1256
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3041202125
- Cited by
- 5
- References
- 2
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Keywords
- primary sclerosing cholangitis, cholangitis, chronic liver disease, inflammatory bowel disease, cholangiocarcinoma risk
- MeSH terms
- Biliary Tract, Digestive System Neoplasms, Humans, Liver Cirrhosis, Cholangitis, Sclerosing, Disease Progression, Risk Assessment, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
